Exact Sciences (EXAS) shares tumbled 5.35% in pre-market trading on Thursday amid multiple price target cuts from Wall Street analysts.
Barclays analyst Luke Sergott lowered the firm's price target on EXAS to $65 from $70, while maintaining an Overweight rating on the stock. BTIG also cut its price target on the molecular diagnostics company to $65 from $75, but kept a Buy rating following Exact Sciences' Q4 results and guidance.
Additionally, Jefferies trimmed its price target on EXAS to $80 from $85 as part of its broader research roundup on U.S. companies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.